Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fragmin
Drug ID BADD_D00974
Description Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indications and Usage It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
Marketing Status Prescription; Discontinued
ATC Code B01AB04
DrugBank ID DB06779
KEGG ID D03353
MeSH ID D017985
PubChem ID Not Available
TTD Drug ID D08PSU
NDC Product Code Not Available
Synonyms Dalteparin | Tedelparin | FR-860 | FR 860 | FR860 | Kabi-2165 | Kabi 2165 | Kabi2165 | Dalteparin Sodium | Sodium, Dalteparin | Fragmin | Fragmine
Chemical Information
Molecular Formula Not Available
CAS Registry Number 9005-49-6
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abscess11.01.08.001--Not Available
Adrenal haemorrhage24.07.01.023; 12.01.02.006; 05.01.03.002--Not Available
Adrenocortical insufficiency acute14.11.01.020; 05.01.02.005--Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Aplasia cutis congenita23.01.04.004; 03.05.01.011--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Arrhythmia02.03.02.001--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Back pain15.03.04.005--
Blood calcium abnormal13.11.01.022--Not Available
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Calcinosis08.03.04.002--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.016--
Coagulation time prolonged13.01.02.006--Not Available
Coma17.02.09.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages